Company intelligence / Profile preview

Doron Therapeutics

Chapel Hill, North Carolina, United Statesdorontherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

Data from a Phase 2 clinical trial were presented at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria, where MOTYS™ was identified as a highly promising program. The company has clinical data from over 350 patients, with pre-clinical evidence suggesting superiority compared to currently available therapies including steroids and hyaluronic acid[2][5].

Therapeutic areas: Rheumatology
Modalities: Biologic drug derived from placental tissue
Industry: Biotech

Drug pipeline

1 asset

motys

Beyond the preview

Go deeper on Doron Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Doron Therapeutics.

Explore the full profile